| Literature DB >> 26075275 |
Abstract
Recombinant proteins are primarily produced from cultures of mammalian, insect, and bacteria cells. In recent years, the development of deconstructed virus-based vectors has allowed plants to become a viable platform for recombinant protein production, with advantages in versatility, speed, cost, scalability, and safety over the current production paradigms. In this paper, we review the recent progress in the methodology of agroinfiltration, a solution to overcome the challenge of transgene delivery into plant cells for large-scale manufacturing of recombinant proteins. General gene delivery methodologies in plants are first summarized, followed by extensive discussion on the application and scalability of each agroinfiltration method. New development of a spray-based agroinfiltration and its application on field-grown plants is highlighted. The discussion of agroinfiltration vectors focuses on their applications for producing complex and heteromultimeric proteins and is updated with the development of bridge vectors. Progress on agroinfiltration in Nicotiana and non-Nicotiana plant hosts is subsequently showcased in context of their applications for producing high-value human biologics and low-cost and high-volume industrial enzymes. These new advancements in agroinfiltration greatly enhance the robustness and scalability of transgene delivery in plants, facilitating the adoption of plant transient expression systems for manufacturing recombinant proteins with a broad range of applications.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26075275 PMCID: PMC4449920 DOI: 10.1155/2015/932161
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Transgene delivery by agroinfiltration into N. benthamiana and lettuce plants. Agrobacteria carrying the expression cassette of GFP or DsRed in geminiviral vectors were syringe-infiltrated into a N. benthamiana leaf (a) and GFP or DsRed expression was observed 4 days after infiltration under UV light (b). Similarly, A. tumefaciens cells harboring the expression cassette of GFP in a geminiviral vector were vacuum infiltrated into a lettuce plant (c) and GFP expression was examined 4 days after infiltration (d). The yellow spot in (b) indicates the leaf area that was coinfiltrated with agrobacteria carrying the expression cassette of GFP and DsRed.
Figure 2N. benthamiana plant growth (a) and agroinfiltration (b) at commercial production scale at Kentucky Bioprocessing LLC.
Figure 3Geminiviral BeYDV vector for expression of recombinant proteins. The left (LB, pink triangle) and right border (RB, pink triangle) delineate the T-DNA construct that will be transferred into plant cells by Agrobacterium. Upon delivery into plant cells, expression of Rep gene produces the Rep protein (brown cloud) that nicks the LIRs (red stars) in the T-DNA to release a single-stranded DNA molecule (between the two yellow arrows). This DNA molecule recircularizes and is copied to make double-stranded DNAs that can replicate by the rolling circle mechanism to produce very high copy numbers of DNA templates (circles) and, in turn, abundant mRNAs of gene of interest (GOI) for the translation of the recombinant protein. Blue star: SIR; pink triangle: LB and RB of the T-DNA; red stars: LIRs; green arrow: gene of interest; brown cloud: Rep protein.
Examples of recombinant proteins produced in plants by agroinfiltration.
| Plant host | Vector | Biologic target | Development stage | References |
|---|---|---|---|---|
|
| Nonviral vector | Influenza A H5N1 HA VLP vaccine | Phase I/II human trial | [ |
|
| TMV | NHL personalized vaccine | Phase I human trial | [ |
|
| CPMV | BTV 4-component VLP vaccine | Preclinical | [ |
|
| TMV/PVX | Tetravalent antibody WNV therapeutic | Preclinical | [ |
|
| TMV | Cellulases for ethanol production | Early development | [ |
|
| TMV/PVX | Ebola immune complex-based vaccine | Preclinical | [ |
|
| TMV, BeYDV, CPMV | HBcAg nonenveloped VLP vaccine | Preclinical | [ |
|
| TMV/PVX, BeYDV | Ebola therapeutics based on MAb | Preclinical | [ |
|
| TMV, BeYDV | Norovirus NVCP VLP vaccine | Preclinical | [ |
|
| TMV/PVX, BeYDV | WNV therapeutics based on MAb | Preclinical | [ |
|
| TMV, BeYDV | WNV DIII vaccine | Preclinical | [ |
HA: hemagglutinin; VLP: virus-like particle; NHL: non-Hodgkin's lymphoma; BTV: bluetongue virus; WT: wild-type; ΔXF: plants with double knockdown of β-1,2-xylose and core α-1,3-fucose; WNV: West Nile virus; HBcAg: hepatitis B core antigen; MAb: monoclonal antibody; NVCP: Norwalk virus capsid protein; DIII: domain III of envelope protein.